Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 278063, 6 pages
http://dx.doi.org/10.1155/2014/278063
Research Article

Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus

13rd Department of Internal Medicine, Metabolism and Gerontology, University Hospital Hradec Králové, Medical Faculty, Charles University, 50005 Hradec Králové, Czech Republic
21st Department of Internal Medicine, Cardioangiology, University Hospital Hradec Králové, Medical Faculty, Charles University, 50005 Hradec Králové, Czech Republic
3Department of Immunology and Alergology, University Hospital Hradec Králové, Medical Faculty, Charles University, 50005 Hradec Králové, Czech Republic
4Department of Cardiosurgery, University Hospital Hradec Králové, Medical Faculty, Charles University, 50005 Hradec Králové, Czech Republic

Received 23 December 2013; Revised 22 February 2014; Accepted 10 March 2014; Published 10 April 2014

Academic Editor: Belma Turan

Copyright © 2014 J. Fortunato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Mallat, G. Lambeau, and A. Tedgui, “Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers,” Circulation, vol. 122, no. 21, pp. 2183–2200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Y. Hui, “Phospholipase A2 enzymes in metabolic and cardiovascular diseases,” Current Opinion in Lipidology, vol. 23, no. 3, pp. 235–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Caslake and C. J. Packard, “Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease,” Current Opinion in Lipidology, vol. 14, no. 4, pp. 347–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Stafforini, “Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2),” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 73–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. H. Macphee, J. J. Nelson, and A. Zalewski, “Lipoprotein-associated phospholipase A2 as a target of therapy,” Current Opinion in Lipidology, vol. 16, no. 4, pp. 442–446, 2005. View at Google Scholar · View at Scopus
  6. A. Zalewski and C. Macphee, “Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 5, pp. 923–931, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Gazi, E. S. Lourida, T. Filippatos, V. Tsimihodimos, M. Elisaf, and A. D. Tselepis, “Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma,” Clinical Chemistry, vol. 51, no. 12, pp. 2264–2273, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kohno, K. Yokokawa, K. Yasunari et al., “Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration,” Circulation, vol. 98, no. 4, pp. 353–359, 1998. View at Google Scholar · View at Scopus
  10. J. Parenica, P. Nemec, J. Tomandl et al., “Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated with transcatheter or surgical aortic valve implantation,” PLoS ONE, vol. 7, no. 12, Article ID e48851, 2012. View at Google Scholar
  11. R. S. Rosenson, “Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes,” Current Opinion in Lipidology, vol. 21, no. 6, pp. 473–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. K. J. Colley, R. L. Wolfert, and M. E. Cobble, “Lipoprotein associated phospholipase A2: role in atherosclerosis and utility as a biomarker for cardiovascular risk,” The EPMA Journal, vol. 2, no. 1, pp. 27–38, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. R. L. Wilensky and C. H. Macphee, “Lipoprotein-associated phospholipase A2 and atherosclerosis,” Current Opinion in Lipidology, vol. 20, no. 5, pp. 415–420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. P. B. Gorelick, “Lipoprotein-associated phospholipase A2 and risk of stroke,” The American Journal of Cardiology, vol. 101, no. 12A, pp. 34F–40F, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Iribarren, M. D. Gross, J. A. Darbinian, D. R. Jacobs Jr., S. Sidney, and C. M. Loria, “Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 216–221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Dohi, K. Miyauchi, S. Okazaki et al., “Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome,” Atherosclerosis, vol. 219, no. 2, pp. 907–912, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. C. Epps and R. L. Wilensky, “Lp-PLA2 a novel risk factor for high-risk coronary and carotid artery disease,” Journal of Internal Medicine, vol. 269, no. 1, pp. 94–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. D. Tselepis and M. J. Chapman, “Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase,” Atherosclerosis Supplements, vol. 3, no. 4, pp. 57–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Ballantyne, R. C. Hoogeveen, H. Bang et al., “Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study,” Circulation, vol. 109, no. 7, pp. 837–842, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Noto, P. Chitkara, and P. Raskin, “The role of lipoprotein-associated phospholipase A2 in the metabolic syndrome and diabetes,” Journal of Diabetes and Its Complications, vol. 20, no. 6, pp. 343–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. Corsetti, D. Ryan, A. J. Moss, D. L. Rainwater, W. Zareba, and C. E. Sparks, “Glycoprotein Ibα polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients,” Diabetes, vol. 56, no. 5, pp. 1429–1435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Sonoki, M. Iwase, N. Sasaki et al., “Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 86, no. 2, pp. 117–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Iwase, K. Sonoki, N. Sasaki et al., “Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment,” Atherosclerosis, vol. 196, no. 2, pp. 931–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Sánchez-Quesada, I. Vinagre, E. D. Juan-Franco et al., “Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution,” The American Journal of Cardiology, vol. 110, no. 1, pp. 67–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. P. Toth, R. J. Simko, S. R. Palli, D. Koselleck, R. A. Quimbo, and M. J. Cziraky, “The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellituss,” Cardiovascular Diabetology, vol. 11, article 109, 2012. View at Publisher · View at Google Scholar
  26. S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. e13–e18, 2004. View at Google Scholar · View at Scopus